Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Collyar: What's In It for Patients?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Opening Session Panel Discussion

Advertisement

Advertisement




Jan
05
Today In Oncology
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Perioperative Camrelizumab Plus Rivoceranib vs Surgery Alone in Hepatocellular Carcinoma
Which First-Line Systemic Therapy Balances Survival and Quality of Life in Advanced Hepatocellular Carcinoma?
Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo